Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer.

@article{Chu2015GastricAS,
  title={Gastric Acid suppression is associated with decreased erlotinib efficacy in non-small-cell lung cancer.},
  author={Michael P. Chu and Sunita Ghosh and Carole R. Chambers and Naveen S Basappa and Charles Andrew Butts and Quincy S-C Chu and David Fenton and Anil Abraham Joy and Randeep S. Sangha and Michael G B Smylie and Michael B Sawyer},
  journal={Clinical lung cancer},
  year={2015},
  volume={16 1},
  pages={33-9}
}
BACKGROUND Erlotinib is a key therapy for advanced NSCLC. Concurrent AS therapy with TKIs might reduce TKI plasma levels. Because of gastroesophageal reflux disease prevalence, this retrospective analysis was undertaken to determine if coadministering erlotinib with AS therapy affected NSCLC outcomes. PATIENTS AND METHODS Records of advanced NSCLC patients who received erlotinib from 2007 to 2012 at a large, centralized, cancer institution were retrospectively reviewed. Pertinent demographic… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
15 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Similar Papers

Loading similar papers…